Physician profile
Ruby L Burden
NPI 1871548586
$2,429.54
in general payments reported to CMS, 2019-2025
18 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.06 · 2022: $516 · 2023: $498 · 2024: $765 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $485.86 | 2021-2025 | Lokelma, Breztri, Airsupra |
| Amgen INC. | $280.68 | 2023-2025 | Repatha, Otezla |
| Neurocrine Biosciences, INC. | $194.02 | 2023-2024 | Ingrezza |
| Abbvie INC. | $179.40 | 2024-2025 | |
| Gilead Sciences, INC. | $170.21 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Ajovy |
| Janssen Pharmaceuticals, INC | $123.91 | 2024 | Xarelto |
| Ani Pharmaceuticals, INC. | $112.58 | 2025 | Purified Cortrophin Gel |
| Dexcom, INC. | $104.00 | 2023 | Dexcom G7 Gss (161) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.91 | 2022 | |
| Novo Nordisk INC | $95.25 | 2022 | |
| Pfizer INC. | $84.02 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $77.55 | 2022 | |
| Acadia Pharmaceuticals INC | $69.40 | 2023 | Nuplazid |
| Paratek Pharmaceuticals, INC. | $63.90 | 2023 | Nuzyra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $61.51 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $61.38 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Burden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.